02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
19:54 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

FDA lifts hold on Aptose blood cancer candidate

Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) said FDA lifted a two-and-a-half year clinical hold on a Phase Ib trial evaluating IV APTO-253 in patients with hematologic malignancies. In 2015, FDA placed a hold on the open-label,...
17:35 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

APTO-253: Development delayed

Aptose said it will “temporarily delay clinical activities” for its IV APTO-253 to allow the company to investigate the cause of manufacturing issues. Aptose said it will prioritize its resources on preclinical cancer candidate CG026806...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

APTO-253: Phase Ib hold

Aptose said it received a response from FDA regarding a clinical hold the agency placed last November on its open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. According to Aptose,...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

APTO-253: Phase Ib hold

Aptose said it submitted a formal response to FDA’s requests following a November 2015 clinical hold on an open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. The company had voluntarily...
07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin-25 (IL-25; IL-17E)

Infectious disease INDICATION: Clostridium Patient sample and mouse studies suggest IL-25 could help treat Clostridium difficile infection (CDI). In patient intestinal tissue samples, levels of IL-25 protein were lower than in samples from healthy volunteers....
07:00 , Jun 13, 2016 |  BC Week In Review  |  Company News

CrystalGenomics, Aptose Biosciences deal

CrystalGenomics granted Aptose an exclusive option to license rights to CG026806 outside of China and Korea. CrystalGenomics will receive an upfront payment of $1 million and is eligible for a $2 million option exercise payment...
02:43 , Jun 9, 2016 |  BC Extra  |  Company News

Aptose, CrystalGenomics in deal for multi-kinase inhibitor

CrystalGenomics Inc. (KOSDAQ:083790) granted Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) an exclusive option to license rights to CG026806 outside of China and Korea. The compound is a small molecule inhibitor of Bruton's tyrosine kinase (Btk) ,...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

APTO-253: Phase Ib hold

FDA placed a clinical hold on an open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. The hold follows a voluntary suspension of dosing and preliminary review that found concerns regarding...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

Aptose Biosciences, Laxai Avanti Life Sciences deal

Aptose partnered with CRO Laxai Avanti Life Sciences to develop next-generation epigenetic-based therapies. Laxai will optimize multiple clinical candidates from Aptose, including candidates to treat hematologic malignancies and solid tumors that Aptose licensed from H....